Ennogen Healthcare International Limited (“Ennogen”) today announced the acquisition of the European commercialisation rights and related intellectual property for Ovestin from Aspen Pharmacare Holdings Limited (“Aspen”).

Ennogen and Aspen will enter a manufacturing and supply agreement under which Aspen will supply the active pharmaceutical ingredient and cream dose form of Ovestin. In addition, Aspen will provide Ennogen with facilitation services for a period of five years.

The acquisition is aligned with Ennogen’s strategic focus on acquiring heritage brands whilst growing its geographic footprint. This acquisition will expand Ennogen’s footprint throughout Europe whilst strengthening its focus on topical products.

Ennogen is a privately owned pharmaceutical and medical device company founded in 2011, with a head office function in Dubai and offices in the UK and Ireland. Ovestin will complement Ennogen’s existing portfolio and enhance its presence in the European pharmaceutical market.

Greenhill acted as adviser to Ennogen in connection with this transaction.